ImmuneOncia Finalizes 81.8 Billion Won Rights Offering at 4,860 Won for IMC-001 Commercialization
- Rights offering finalized: 16,830,200 common shares at 4,860 won each, raising 81.8 billion won (22.4% below initial 6,260 won)
- Use of proceeds: 78.995 billion for IMC-001 commercialization (CMC), 2.8 billion for R&D (toxicology); BLA costs excluded
- Dilution: 22.63% of existing 74,363,829 shares
- Financials: FY2025 net loss 27.3 billion, FY2026E net loss 62.5 billion. Post-offering capital erosion ratio improves to -4.94% but pretax loss ratio worsens to 130.84%
- Cash depletion risk if tech transfers fail: Case 2 (no revenue) leads to negative cash of -76.5 billion by 2028, requiring additional funding (private CB, etc.)
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: [Confirmation of Issuance Terms] Securities Registration Statement (Equity Securities)
- Company: ImmuneOncia Therapeutics (424870)
- Submission: ImmuneOncia Therapeutics, Inc.
- Receipt: 05-11-2026